ReviewWorld journal of clinical oncology2021
Re-irradiation for high-grade gliomas: Has anything changed?
Review in World journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- PET-based Radiomics Analysis for Predicting Prognosis and Differentiation Treatment-Related Changes in Glioma: A Systematic Review.Journal of biomedical physics & engineering · 2026Article
- Precision reirradiation in recurrent CNS tumors integrating biology techniques and multimodal care.Discover oncology · 2026Review
- Prolonged survival in pediatric diffuse intrinsic pontine glioma following intensity-modulated radiation therapy: a case report.Journal of medical case reports · 2026Article
- Patterns of failure following stereotactic radiosurgery salvage for recurrent high-grade glioma.Journal of neuro-oncology · 2026Article
- Article
- Biologically Guided Gamma Knife Dose Painting for Recurrent High-Grade Gliomas: A Retrospective Study Using Functional MRI Techniques.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Article
- Article
- Pattern of recurrence after fractionated stereotactic reirradiation in adult glioblastoma.Radiation oncology (London, England) · 2025Article
- Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology.Pharmaceutics · 2025Review
- A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy.Discover oncology · 2024Article
- Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects.OncoTargets and therapy · 2023Review
- Management of Recurrent Glioblastomas: What Can We Learn from the French Glioblastoma Biobank?Cancers · 2022Article
- How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatment.Journal of neuro-oncology · 2022Article
- Relapsing High-Grade Glioma from Peritumoral Zone: Critical Review of Radiotherapy Treatment Options.Brain sciences · 2022Review
- Results from a phase I study of 4-Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimal management after recurrence or progression of high-grade gliomas is still undefined and remains a challenge for neuro-oncology multidisciplinary teams. Improved radiation therapy techniques, new imaging methods, published experience, and a better radiobiological knowledge of brain tissue have positioned re-irradiation (re-RT) as an option for many of these patients. Decisions must be individualized, taking into account the pattern of relapse, previous treatment, and functional status, as well as the patient's preferences and expected quality of life. Many questions remain unanswered with respect to re-RT: Who is the most appropriate candidate, which dose and fractionation are most effective, how to define the target volume, which imaging technique is best for planning, and what is the optimal timing? This review will focus on describing the most relevant studies that include re-RT as salvage therapy, with the aim of simplifying decision-making and designing the best available therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.